argenex (ARGX) Expected to Announce Earnings on Thursday

argenex (NASDAQ:ARGX) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect argenex to post earnings of $6.05 per share and revenue of $1.3048 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

argenex Trading Down 2.2%

argenex stock opened at $826.25 on Tuesday. The firm has a 50-day moving average of $830.73 and a 200-day moving average of $808.82. The firm has a market cap of $51.13 billion, a P/E ratio of 35.48, a P/E/G ratio of 0.73 and a beta of 0.37. argenex has a 1-year low of $510.05 and a 1-year high of $934.62.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Royal Bank Of Canada upped their price target on argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Wedbush restated an “outperform” rating and set a $1,000.00 target price on shares of argenex in a report on Wednesday, January 14th. Zacks Research lowered argenex from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 22nd. Morgan Stanley boosted their price objective on shares of argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Finally, Evercore upped their price objective on shares of argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, argenex currently has an average rating of “Moderate Buy” and an average price target of $986.78.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Invesco Ltd. boosted its stake in argenex by 390.4% during the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after acquiring an additional 331,489 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares in the last quarter. Corient Private Wealth LLC boosted its position in shares of argenex by 12,441.8% in the 4th quarter. Corient Private Wealth LLC now owns 246,572 shares of the company’s stock worth $207,355,000 after purchasing an additional 244,606 shares in the last quarter. Finally, Woodline Partners LP grew its stake in shares of argenex by 320.8% in the 3rd quarter. Woodline Partners LP now owns 169,476 shares of the company’s stock worth $124,999,000 after buying an additional 129,205 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.